Prostatype Genomics EV/EBITDA

Que fait Prostatype Genomics ? Prostatype Genomics AB generates revenue by manufacturing and selling the Prostatype Test System, a comprehensive prognostic package including the Prostatype RTqPCR kit, patient database, evaluation software, and P-score accessories. The company targets clinicians and patients who require decision support for prostate cancer treatment after diagnosis, leveraging gene expression analysis of cancer cells from prostate tissue. The Prostatype Test System combines a specialized kit, database, software, and algorithm-driven data analysis to assess cancer aggressiveness and guide treatment choices. The firm's primary customers are healthcare professionals and institutions involved in prostate cancer care, utilizing the Prostatype RTqPCR kit for gene expression testing. The system's components—Prostatype RTqPCR kit, patient database, evaluation software, and P-score—are sold as an integrated solution, with the evaluation software and P-score providing algorithm-based decision support. This approach ensures clinicians receive tailored treatment recommendations based on individual patient data. Prostatype Genomics est l'une des entreprises les plus populaires sur Eulerpool.